prof.dr.tayfun baĞiŞ 15/05/2013 tjod. terminologyaimmethodology natural cycle ivfsingle oocyteno...
TRANSCRIPT
![Page 1: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/1.jpg)
IVF’te Doğal Siklus, Minimal Stimülasyon: Kime? Gerçek bir
alternatif mi?
Prof.Dr.Tayfun BAĞIŞ15/05/2013
TJOD
![Page 2: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/2.jpg)
![Page 3: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/3.jpg)
Terminology Aim Methodology
Natural cycle IVF Single oocyte No medicationNo luteal support
Modified NC IVF Single oocyte HCG only, antagonist, and/or FSH/HMG add back (up to 150 IU)Luteal support (HCG or P)
Mild IVF 2-7 oocytes Fixed low dose FSH/HMG (up to 150 IU), oral compounds and antagonist
Conventional IVF ≥8 oocytes Conventional FSH/HMG dose, agonist or antagonist
![Page 4: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/4.jpg)
Current ovarian stimulation approaches Mild stimulation approaches
Time consuming and complex stimulation regimens
Less complexLess time consuming
High costs Cheaper (making IVF more accessible for a broader patient population)
Much patient discomfort Reduced chances for discomfort
Short-term complications—ovarian hysterstimulation syndrome (OHSS)
Reduced chances for complications
High drop-out rates Reduced chances for drop-out
Supraphysiological steroid levels with possible implications
Effects on oocyte qualityEffects on endometrial receptivity
Emphasize additional pregnancy chances from cryopreserved embryos
Reduced chances for cryopreserved embryos
Emphasize maximizing pregnancy rates per cycle Emphasize maximizing chances for healthy children born per started treatment at reasonable cost, patient discomfort and chances for complications
![Page 5: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/5.jpg)
NATURAL CYCLE IVF AND
MNC IVF
![Page 6: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/6.jpg)
• The per cycle costs of NC IVF is 20-23% of stimulated IVF.
![Page 7: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/7.jpg)
![Page 8: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/8.jpg)
4 cycles NC IVF
Cumulative PR 46 %LBR 32%
(Nargund et al., 2001)
![Page 9: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/9.jpg)
![Page 10: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/10.jpg)
![Page 11: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/11.jpg)
![Page 12: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/12.jpg)
![Page 13: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/13.jpg)
501 cyclesIn cycles <40 years
NC IVF MS P
Cycles with oocytes 61.3 % 77.5 % 0.03PR/cycle 9.3 % 24.2 % 0.01PR/ET 18.4 % 36.7 % 0.01
No difference in women older than 40 years
![Page 14: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/14.jpg)
![Page 15: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/15.jpg)
![Page 16: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/16.jpg)
POR N:136
390 cycles
CONTROL N:28
79 cycles
P
Cycles with oocytes 75 % 78 % NSCycles with ET 42 % 59 % 0.011(+) HCG/cycle 4.6 % 15.2 % 0.0005LBR/cycle 2.6 % 8.9 % 0.006(+) HCG/patient 12.5 % 35.7 % 0.003LBR/patient 7.4 % 25 % 0.005
![Page 17: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/17.jpg)
MNC IVF
Nonrandomized studies in POR patients
Success rates 0-14%
Elizur et al., 2005; Castelo-Branco et al., 2004; Kolibianakis et al., 2004; Weghofer
et al., 2004; Hur et al., 2005
![Page 18: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/18.jpg)
![Page 19: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/19.jpg)
![Page 20: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/20.jpg)
MNC IVF Pelinck 2006
Cycles started 844
Cycles canceled before HCG 3 %
OR planned 90.5 %
Planned OR canceled 9 %
OR performed 82.3%
OR successful 75.3%
Fertilization/OR 71.9%
Embryo transfer 37.6 %
OPR/cycle 8.3%
OPR/ET 22.1%
![Page 21: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/21.jpg)
CLOMIPHENE CITRATEbased protocols
![Page 22: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/22.jpg)
![Page 23: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/23.jpg)
![Page 24: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/24.jpg)
![Page 25: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/25.jpg)
![Page 26: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/26.jpg)
![Page 27: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/27.jpg)
window
threshold
recruitment
menses
selection dominance
atresia
FSH
leve
lFo
llicl
e si
ze
Luteo-follicular transitison
![Page 28: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/28.jpg)
![Page 29: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/29.jpg)
![Page 30: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/30.jpg)
![Page 31: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/31.jpg)
![Page 32: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/32.jpg)
![Page 33: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/33.jpg)
![Page 34: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/34.jpg)
![Page 35: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/35.jpg)
![Page 36: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/36.jpg)
![Page 37: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/37.jpg)
![Page 38: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/38.jpg)
![Page 39: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/39.jpg)
![Page 40: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/40.jpg)
![Page 41: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/41.jpg)
![Page 42: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/42.jpg)
![Page 43: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/43.jpg)
![Page 44: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/44.jpg)
![Page 45: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/45.jpg)
![Page 46: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/46.jpg)
![Page 47: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/47.jpg)
![Page 48: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/48.jpg)
![Page 49: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/49.jpg)
![Page 50: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/50.jpg)
![Page 51: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/51.jpg)
![Page 52: Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbf5503460f94ab3aa5/html5/thumbnails/52.jpg)
CONCLUSIONS:Strength:• GnRH antagonist advantages• Reduced complexity, patient discomfort and risk• Reduced cost• Beneficial effect on oocyte/embryo quality
Weakness:• Lower PR/cycle• Excessive responses• Cost of medications is still high• Less margin for suboptimal laboratory performance• Fewer embryos for cryopreservation• Difficult programming of the cycle